| Segment Reporting |
Note
7 – Segment Reporting
We
manage our operations as a single segment, focused on developing the next generation of cancer therapy drugs. As our chief operating
decision maker (CODM), our CEO manages and allocates resources at a consolidated level. He assesses performance, monitors budget versus
actual results, and decides how to allocate resources based on net loss that also is reported on the consolidated statement of operations
and comprehensive loss as consolidated net loss.
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three and six months ended June 30, 2025 and 2024:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| | |
Three Months Ended June 30, | | |
Six Months Ended June 30, | |
| | |
2025 | | |
2024 | | |
2025 | | |
2024 | |
| Preclinical, clinical trial and other costs | |
$ | 2,142,229 | | |
$ | 1,261,720 | | |
$ | 3,339,263 | | |
$ | 2,293,001 | |
| Research and development personnel expense(1) | |
| 305,057 | | |
| 468,724 | | |
| 696,504 | | |
| 976,554 | |
| Research and development personnel
expense | |
| 305,057 | | |
| 468,724 | | |
| 696,504 | | |
| 976,554 | |
| General and administrative personnel expense(2) | |
| 628,330 | | |
| 445,620 | | |
| 1,302,167 | | |
| 964,409 | |
| General and administrative
personnel expense | |
| 628,330 | | |
| 445,620 | | |
| 1,302,167 | | |
| 964,409 | |
| Administrative and facilities expense(3) | |
| 875,167 | | |
| 905,960 | | |
| 1,459,839 | | |
| 1,657,658 | |
| Administrative and facilities
expense | |
| 875,167 | | |
| 905,960 | | |
| 1,459,839 | | |
| 1,657,658 | |
| Other income, net | |
| (16,865 | ) | |
| (71,698 | ) | |
| (29,450 | ) | |
| (154,915 | ) |
| Total | |
$ | 3,933,918 | | |
$ | 3,010,326 | | |
$ | 6,768,323 | | |
$ | 5,736,707 | |
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $8,613 and $45,583 for the three months ended
June 30, 2025 and 2024, respectively, and $55,333 and $76,704 for the six months ended June 30, 2025 and 2024, respectively. |
| |
|
|
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $122,655 and $40,309 for the three months
ended June 30, 2025 and 2024, respectively, and $245,310 and 79,180 for the six months ended June 30, 2025 and 2024, respectively,
and are net of reimbursements received from CorLyst, LLC. |
| |
|
|
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
|